Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar 28;4(127):127ps8.
doi: 10.1126/scitranslmed.3003634.

Raising the bar: the curative potential of human cancer immunotherapy

Steven A Rosenberg  1
Affiliations
Review

Raising the bar: the curative potential of human cancer immunotherapy

Steven A Rosenberg. Sci Transl Med. .

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. A schema for personalized immunotherapy using gene-modified cells.
The antigen expression is determined on a tumor biopsy. An appropriate T cell receptor that recognizes that specific antigen is then retrovirally transduced into the patients’ autologous lymphocytes. The lymphocytes are expanded in vitro and infused.
See this image and copyright information in PMC

References

    1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011). - PMC - PubMed
    1. Rosenberg SA, Cell transfer immunotherapy for meta-static solid cancer—What clinicians need to know. Nat. Rev. Clin. Oncol 8, 577–585 (2011). - PMC - PubMed
    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol 25, 1960–1966 (2007). - PubMed
    1. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R, Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J. Natl. Cancer Inst. 102, 230–243 (2010). - PubMed
    1. Morgan DA, Ruscetti FW, Gallo RG, Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007–1008 (1976). - PubMed

Substances

LinkOut - more resources